Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo

Arthritis and Rheumatism
J W G JacobsJohannes W J W Bijlsma

Abstract

In a previous clinical trial of patients with early rheumatoid arthritis (RA), it was determined that patients who received 10 mg of prednisone per day for 2 years had less radiographic joint damage compared with those who received placebo. Our goal was to investigate whether this beneficial effect persisted after the end of the trial. A blinded assessment of radiographic joint damage was performed approximately 3 years after the end of the original 2-year study. Twenty-four patients from the original prednisone group (60%) and 28 patients from the original placebo group (68%) participated in this followup study. At the end of the original trial, prednisone dosages were tapered down in the prednisone group and stopped, if possible. Patients from the original prednisone group took prednisone during 35% of the followup period (approximately 1 year) at a mean daily dose of approximately 5 mg. Two patients from the original placebo group started taking prednisone during followup. Radiographs of the hands and feet were scored according to the van der Heijde modification of the Sharp method. During 3 additional years of followup, radiographic scores showed significantly less progression in the original prednisone group than in the or...Continue Reading

References

Oct 3, 2000·Arthritis and Rheumatism·H M HulsmansJ W Bijlsma
Oct 19, 2000·Arthritis and Rheumatism·E M Gravallese, S R Goldring
Jan 20, 2004·Arthritis and Rheumatism·John R Kirwan
Mar 17, 2004·Arthritis and Rheumatism·Robert Landewé, Désirée van der Heijde
May 14, 2004·Annals of the Rheumatic Diseases·J R KirwanF Van den Bosch
Jul 29, 2004·JAMA : the Journal of the American Medical Association·Lorenz C Hofbauer, Michael Schoppet
Jan 11, 2005·Rheumatic Diseases Clinics of North America·Alfonse T MasiJohannes W G Jacobs
Apr 9, 2005·Arthritis and Rheumatism·Wim B van den Berg, Piet L C M van Riel

❮ Previous
Next ❯

Citations

Jun 16, 2007·Zeitschrift für Rheumatologie·F ButtgereitUNKNOWN Kommission Pharmakotherapie der DGRh
Jan 22, 2013·Drugs·Roberto CaporaliCarlomaurizio Montecucco
Dec 2, 2010·Nature Reviews. Rheumatology·Jos N HoesJohannes W J Bijlsma
Jun 15, 2012·Rheumatology·Johannes W J Bijlsma
Apr 7, 2007·Current Opinion in Rheumatology·Eric F Morand
Apr 7, 2007·Current Opinion in Rheumatology·John Kirwan, Lynsey Power
Aug 2, 2012·Therapeutic Advances in Musculoskeletal Disease·Lynsey Clarke, John Kirwan
May 5, 2010·Clinical Medicine : Journal of the Royal College of Physicians of London·John R Kirwan
Jan 23, 2015·Arthritis Research & Therapy·Maurizio CutoloCarmen Pizzorni
Jan 23, 2015·Arthritis Research & Therapy·Marlies C van der GoesJohannes W Bijlsma
Apr 11, 2014·Expert Review of Clinical Immunology·Marco Krasselt, Christoph Baerwald
Dec 7, 2013·Expert Review of Clinical Immunology·Cecilia Mercieca, John R Kirwan
Nov 15, 2011·Reumatología clinica·Elena Alonso Blanco-MoralesMaría Ángeles Gantes Pedraza
Dec 6, 2011·Best Practice & Research. Clinical Rheumatology·M S JurgensJ W J Bijlsma
Mar 15, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Wouter HofkensPeter L van Lent
Apr 1, 2009·Arthritis and Rheumatism·John R Kirwan, Maarten Boers Msc
Apr 20, 2010·Annals of the New York Academy of Sciences·Johannes W J BijlsmaJohn Kirwan
May 13, 2014·Annals of the New York Academy of Sciences·Tânia Santiago, José António P da Silva
Mar 20, 2014·Annals of the New York Academy of Sciences·Johannes W J Bijlsma, Johannes W G Jacobs
Jul 7, 2009·Expert Opinion on Therapeutic Patents·Ling-Dong QuanDong Wang
Feb 24, 2009·Best Practice & Research. Clinical Rheumatology·David L Scott
Jun 5, 2013·Seminars in Arthritis and Rheumatism·Rainer H StraubMaurizio Cutolo
Jan 10, 2018·Calcified Tissue International·Melek Güler-YükselWillem F Lems
Mar 3, 2018·The Journal of Rheumatology·Johannes W G Jacobs, José A Pereira DA Silva
Oct 31, 2007·Arthritis and Rheumatism·Willem F Lems
Jun 15, 2021·Frontiers in Pharmacology·Shahin ShamsJudith F Ashouri
Oct 29, 2021·ACR Open Rheumatology·Kathleen M AndersenUNKNOWN CATCH Investigators

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.